ECOG-ACRIN EA5163

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

For more information about this clinical trial, click here

Schema & Eligibility ECOG-ACRIN EA5163

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Mercy Hospital, St. Louis, MO
Mercy Hospital, Joplin, MO

Ask your physician about participating in this clinical trial or call us.